NEW JERSEY HOSPITAL ASSOCIATION for NEW JERSEY HOSPITAL ASSOCIATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare: Strongly advocated in support of NJHAs application to extend and expand our gainsharing pilot program through CMMIs Model 1 (Physician/Hospital Gainsharing) Bundled Payments for Care Improvement Initiative. Express strong opposition to the automatic 2 percent cuts to acute and post acute providers contained in last years Budget Control Act that are expected to take effect in January. Medicare provider payments would sustain $11 billion in cuts beginning in January under sequestration cuts. Oppose targeting cuts to healthcare programs to avert these looming across the board budget cuts. Urge support for increased GME funding; Supportive of a physician fee payment fix to halt a scheduled 27 percent Medicare cut to physicians in 2013 but not pay for with cuts to providers. Support extension of Section 508 of the MMA. Urge NJ Delegation to support rescinding proposed coding offset provisions in the FY2013 proposed IPPS rule that would have cost New Jersey hospitals $101 million in FY 2013. The rule proposed a combined 2.7 percent reduction to the market basket for documentation and coding adjustments, which is comprised of 1.9 percent for 2008 and 2009 and 0.8 percent for 2010.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KIMBERLY CHAMPI KRENIK | — |
Pharmacy PHA
Support provisions included in S. 3187, the Food and Drug Administration Safety and Innovation Act, which would help speed safe and effective medical products to patients and maintain our nations role as a leader in biomedical innovation. This legislation will drive timely review of new innovator drugs and medical devices, enhance the safety of the drug supply chain in an increasingly globalized market, increase incentives for the development of new antibiotics, renew mechanisms to ensure that childrens medicines are appropriately tested and labeled, and expedite the development and review of certain drugs for the treatment of serious or life-threatening diseases and conditions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KIMBERLY CHAMPI KRENIK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.